HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More

This article was originally published in The Tan Sheet

Executive Summary

FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities

You may also be interested in...

Synthetics Stance In NDI Guidance Raises Red Flag For Industry

FDA's draft guidance on new dietary ingredient notifications already is arousing fierce pushback from the supplement industry over what constitutes an NDI and which substances cannot be dietary ingredients at all.

FDA Proposes Rule On Gluten-Free Labeling

Food products with "gluten-free" claims will be misbranded if they do not meet the conditions of a proposed rule FDA published in the Jan. 23 Federal Register

FDA Requiring GRAS-Level Safety Standards For NDI Submissions, Experts Say

FDA has gradually raised the safety standard for new dietary ingredients above the level intended by DSHEA, according to several experts

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts